T W Kurtz

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi New treatment strategies for patients with hypertension and insulin resistance
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA
    Am J Med 119:S24-30. 2006
  2. ncbi Differential pharmacology and benefit/risk of azilsartan compared to other sartans
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, CA 94107, USA
    Vasc Health Risk Manag 8:133-43. 2012
  3. ncbi Recent advances in genetics of the spontaneously hypertensive rat
    Michal Pravenec
    Institute of Physiology, Academy of Sciences of the Czech Republic, Videnska 1083, Prague 4, Czech Republic
    Curr Hypertens Rep 12:5-9. 2010
  4. ncbi Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA
    J Hypertens 22:2253-61. 2004
  5. ncbi Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator
    T W Kurtz
    Laboratory of Medicine, University of California San Francisco, 185 Berry Street, Suite 290, San Francisco, CA 94107, USA
    Acta Diabetol 42:S9-16. 2005
  6. ncbi Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, California, USA
    Am J Hypertens 21:852-9. 2008
  7. ncbi Beyond the classic angiotensin-receptor-blocker profile
    Theodore W Kurtz
    Laboratory Medicine, University of California, San Francisco, CA 94107, USA
    Nat Clin Pract Cardiovasc Med 5:S19-26. 2008
  8. ncbi Next generation multifunctional angiotensin receptor blockers
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA
    Hypertens Res 32:826-34. 2009
  9. ncbi Genome-wide association studies will unlock the genetic basis of hypertension.: con side of the argument
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Hypertension 56:1021-5. 2010
  10. ncbi Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat
    E St Lezin
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Hypertension 34:187-91. 1999

Research Grants

  1. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
  2. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
  3. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
  4. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 1999
  5. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2001
  6. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore W Kurtz; Fiscal Year: 2010

Collaborators

  • Stephen C Benson
  • W Liu
  • M Pravenec
  • A K Bidani
  • J Wang
  • R C Morris
  • Toshio Ogihara
  • Harrihar A Pershadsingh
  • R L Davisson
  • Karen Griffin
  • John E Hall
  • Dj Pennell
  • Stuart A Cook
  • Ken Sugimoto
  • Nathan R Qi
  • Cassia S Mizuno
  • Amar G Chittiboyina
  • Mitchell A Avery
  • Meenakshi S Venkatraman
  • E St Lezin
  • Enrico Petretto
  • Vladimir Kren
  • Vaclav Zidek
  • Ludmila Kazdova
  • Christopher I Ho
  • Sumangala P Rao
  • Daniel F Catanzaro
  • V Zidek
  • V Kren
  • Masaya Hyakukoku
  • Jonathan Mangion
  • Han Lu
  • Chris Kiesewetter
  • Matthew Benson
  • Rizwan Sarwar
  • Mande K Kumaran
  • Ian Grieve
  • Miroslava Simakova
  • Lolita M Corpuz
  • Blanche Schroen
  • Elena S Tasheva
  • Megan D Webb
  • Phillip J Muckett
  • Judith Fischer
  • Yigal M Pinto
  • Prakash P Punjabi
  • Gary W Conrad
  • Timothy J Aitman
  • Sanjay K Prasad
  • Norbert Hubner
  • Akshay Patny
  • Prashant V Desai
  • N Wang
  • Vladimir Landa
  • Petr Mlejnek
  • Amar Chittiboyina
  • Charles N Ellis
  • Josef Meingassner
  • James Varani
  • Joseph C Dunbar
  • Monique Churchill
  • Karen Lapanowski
  • Crystal McRae
  • E M St Lezin
  • Y Yang
  • N Qi
  • P C Churchill
  • M Picken
  • M C Churchill
  • A L Wong
  • S Lu
  • I A Reid
  • H J Jacob
  • D E Stec
  • R J Roman

Detail Information

Publications37

  1. ncbi New treatment strategies for patients with hypertension and insulin resistance
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA
    Am J Med 119:S24-30. 2006
    ....
  2. ncbi Differential pharmacology and benefit/risk of azilsartan compared to other sartans
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, CA 94107, USA
    Vasc Health Risk Manag 8:133-43. 2012
    ....
  3. ncbi Recent advances in genetics of the spontaneously hypertensive rat
    Michal Pravenec
    Institute of Physiology, Academy of Sciences of the Czech Republic, Videnska 1083, Prague 4, Czech Republic
    Curr Hypertens Rep 12:5-9. 2010
    ....
  4. ncbi Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA
    J Hypertens 22:2253-61. 2004
    ....
  5. ncbi Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator
    T W Kurtz
    Laboratory of Medicine, University of California San Francisco, 185 Berry Street, Suite 290, San Francisco, CA 94107, USA
    Acta Diabetol 42:S9-16. 2005
    ..If the preliminary data are supported by the results of ongoing large-scale clinical studies, telmisartan could have a central role in the prevention and treatment of metabolic syndrome, diabetes and atherosclerosis...
  6. ncbi Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, California, USA
    Am J Hypertens 21:852-9. 2008
    ....
  7. ncbi Beyond the classic angiotensin-receptor-blocker profile
    Theodore W Kurtz
    Laboratory Medicine, University of California, San Francisco, CA 94107, USA
    Nat Clin Pract Cardiovasc Med 5:S19-26. 2008
    ....
  8. ncbi Next generation multifunctional angiotensin receptor blockers
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA
    Hypertens Res 32:826-34. 2009
    ....
  9. ncbi Genome-wide association studies will unlock the genetic basis of hypertension.: con side of the argument
    Theodore W Kurtz
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Hypertension 56:1021-5. 2010
    ....
  10. ncbi Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat
    E St Lezin
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Hypertension 34:187-91. 1999
    ..BN-D1Mit3/Igf2 congenic strain. This congenic strain represents an important new model for the fine mapping of gene(s) on chromosome 1 that affect susceptibility to hypertension-induced renal injury in the rat...
  11. ncbi Effects of renin gene transfer on blood pressure and renin gene expression in a congenic strain of Dahl salt-resistant rats
    E M St Lezin
    Department of Laboratory Medicine, University of California, San Francisco 94143, USA
    J Clin Invest 97:522-7. 1996
    ....
  12. ncbi Transcription-modulating drugs: a new frontier in the treatment of essential hypertension
    T W Kurtz
    From the Departments of Laboratory Medicine and Medicine, University of California at San Francisco, USA
    Hypertension 32:380-6. 1998
    ....
  13. ncbi Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway
    Ken Sugimoto
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    J Hypertens 26:1209-15. 2008
    ..As muscle fatty acid oxidation is a major determinant of energy expenditure, we investigated the effects of telmisartan on skeletal muscle fatty acid oxidation in a rat model of the metabolic syndrome...
  14. ncbi Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis
    Ken Sugimoto
    Department of Laboratory Medicine, University of California, San Francisco, CA 94107, USA
    Hypertension 47:1003-9. 2006
    ....
  15. ncbi A new transgenic rat model of hepatic steatosis and the metabolic syndrome
    Nathan R Qi
    Department of Laboratory Medicine, University of California, San Francisco, USA
    Hypertension 45:1004-11. 2005
    ....
  16. ncbi Genetic analysis of rat chromosome 1 and the Sa gene in spontaneous hypertension
    E St Lezin
    Department of Laboratory Medicine, University of California, San Francisco 94143 1613, USA
    Hypertension 35:225-30. 2000
    ....
  17. ncbi Linkage mapping of the Na-K-2Cl cotransporter gene (Slc12a1) to rat chromosome 3
    J Wang
    Department of Laboratory Medicine, University of California, San Francisco, California 94143, USA
    Mamm Genome 8:379. 1997
  18. ncbi Genetics of Cd36 and the hypertension metabolic syndrome
    Michal Pravenec
    Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic; and the Department of Laboratory Medicine, University of California, San Francisco, CA
    Semin Nephrol 22:148-53. 2002
    ..These findings show that a primary defect in fatty acid transport can promote disordered carbohydrate metabolism in the SHR and show the power of advanced genome technologies for identifying QTL at the molecular level...
  19. ncbi Sodium-calcium interactions and salt-sensitive hypertension
    T W Kurtz
    Department of Laboratory Medicine, School of Medicine, University of California, San Francisco 94143-0134
    Am J Hypertens 3:152S-155S. 1990
    ....
  20. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  21. ncbi Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
    Stephen C Benson
    Department of Biological Sciences, California State University, East Bay, Hayward, CA 94542, USA
    J Hypertens 26:973-80. 2008
    ..Few studies have directly compared the effects of different angiotensin receptor blockers (ARBs) on mechanisms involved in the pathogenesis of cardiovascular disease...
  22. ncbi Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease
    Harrihar A Pershadsingh
    Diabetes Care 27:1015. 2004
  23. ncbi False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system?
    Theodore W Kurtz
    Hypertension 41:193-6. 2003
  24. ncbi Insulin mediated hemodynamic responses in spontaneous hypertensive rats (SHRs): effect of chromosome 4 gene transfer
    Sumangala P Rao
    Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan 48201-1928, USA
    Clin Exp Hypertens 25:131-42. 2003
    ..These findings indicate that transfer of segment of chromosome 4 from Brown Norway rats onto spontaneous hypertensive background eliminates hyperinsulinemia and pressor effects of insulin...
  25. ncbi Identification of renal Cd36 as a determinant of blood pressure and risk for hypertension
    Michal Pravenec
    Institute of Physiology and Center for Applied Genomics, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic
    Nat Genet 40:952-4. 2008
    ....
  26. ncbi Gene expression profiling in hypertension research: a critical perspective
    Michal Pravenec
    Institute of Physiology, Czech Academy of Sciences and The Center for Integrated Genomics, Prague, Czech Republic
    Hypertension 41:3-8. 2003
    ..In this review, we offer a critical perspective on the use of gene expression profiling in hypertension research and discuss some emerging strategies for taking this technology beyond the limits of correlational and descriptive studies...
  27. ncbi Target organ damage in hypertension: mechanisms, prevention, and management
    Daniel F Catanzaro
    Weill Medical College, Cornell University, Cardiovascular Center, New York, New York 10021, USA
    Am J Hypertens 15:1117-8. 2002
  28. ncbi Genetic analysis of metabolic defects in the spontaneously hypertensive rat
    Michal Pravenec
    Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, 12800 Prague, Czech Republic
    Mamm Genome 13:253-8. 2002
    ..These findings suggest that closely linked genes on Chr 19, or perhaps even a single gene with pleiotropic effects, influence the clustering of metabolic disturbances in the SHR-BN model...
  29. ncbi Recommendations for blood pressure measurement in humans and experimental animals: part 2: blood pressure measurement in experimental animals: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart A
    Theodore W Kurtz
    Arterioscler Thromb Vasc Biol 25:e22-33. 2005
    ..Selection of the methods to be used should ultimately be guided by the study objectives to insure that the techniques chosen are appropriate for the experimental questions being explored...
  30. ncbi Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass
    Enrico Petretto
    Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
    Nat Genet 40:546-52. 2008
    ..Taken together, these data implicate Ogn as a key regulator of LVM in rats, mice and humans, and suggest that Ogn modifies the hypertrophic response to extrinsic factors such as hypertension and aortic stenosis...
  31. ncbi Type 2 diabetes and oral antihyperglycemic drugs
    Cassia S Mizuno
    Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS 38677 1848, USA
    Curr Med Chem 15:61-74. 2008
    ..In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes...
  32. ncbi Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat
    Michal Pravenec
    Institute of Physiology and Center for Applied Genomics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
    Hypertension 51:148-53. 2008
    ....
  33. ncbi Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies
    Michal Pravenec
    Institute of Physiology and Center for Applied Genomics, Czech Academy of Sciences, Prague, Czech Republic
    Hypertension 49:941-52. 2007
    ....
  34. ncbi Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists
    Amar G Chittiboyina
    Laboratory for Applied Drug Design and Synthesis, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, 38677, USA
    J Med Chem 49:4072-84. 2006
    ..These novel compounds may prove efficacious not only in the treatment of Type 2 diabetes, but also atherosclerosis, prevention of vascular restenosis, and inflammatory skin diseases...
  35. ncbi Alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases
    Meenakshi S Venkatraman
    Department Medicinal Chemistry, University of Mississippi, University, MS, USA
    Arch Dermatol Res 296:97-104. 2004
    ..These findings suggest that water-soluble lipoic acid-based thiazolidinediones may be efficacious as oral and topical agents for treating inflammatory skin conditions such as contact dermatitis, atopic dermatitis, and psoriasis...
  36. ncbi Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart A
    Theodore W Kurtz
    Hypertension 45:299-310. 2005
    ..Selection of the methods to be used should ultimately be guided by the study objectives to insure that the techniques chosen are appropriate for the experimental questions being explored...
  37. ncbi Recommendations for blood pressure measurement in animals: summary of an AHA scientific statement from the Council on High Blood Pressure Research, Professional and Public Education Subcommittee
    Theodore W Kurtz
    Arterioscler Thromb Vasc Biol 25:478-9. 2005

Research Grants23

  1. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
    ....
  2. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  3. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
    ..Hypertension candidate genes will then be isolated using cDNA screening techniques to identify genes expressed in the brain, adrenal gland, or kidney that map within this chromosome region. ..
  4. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 1999
    ....
  5. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2001
    ..Finally, they will distribute these strains to other investigators also interested in studying pathophysiologic mechanisms whereby selected chromosome regions may influence cardiovascular function and BP. ..
  6. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore W Kurtz; Fiscal Year: 2010
    ..This project is designed to investigate genetic factors that influence the development of the metabolic syndrome and ultimately help identify new targets for prevention and treatment of diabetes and cardiovascular disease. ..